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Abstract
Background
With increasing adverse cardiovascular disease (CVD) outcomes in HIV/AIDS patients, the
possible contribution of antiretroviral therapy (ART) to the prevailing CVD epidemic in sub-
Saharan Africa (SSA) through its effect on CVD risk factors has rather been under investi-
gated. This study aimed to assess the extent to which ART is associated with hypertension,
diabetes mellitus (DM) and dyslipidemia in SSA.
Methods
This is a systematic review and meta-analysis of studies from SSA, published between Jan-
uary 1946 and December 2017, from Medline, Embase, Africa-wide Information, the
Cochrane library, African Index and Medicus databases. Both observational and interven-
tional studies with comparable ART-treated and ART-naïve populations were selected and
data was extracted from eligible studies. Pooled estimates of the effect of ART on the out-
comes of interest (hypertension, diabetes and abnormal lipid profiles) were obtained using
random effects meta-analysis, and meta-regression analysis was used to explore between-
study heterogeneity.
Results
Twenty cross-sectional studies were included involving 5386 participants. There was no
association between ART use and hypertension (OR: 1.9, 95%CI: 0.96–3.76, n = 8, I2 =
73.8%) and DM (OR: 2.53, 95%CI: 0.87–7.35, n = 8, I2 = 73.8%). ART use was associated
with high total cholesterol (OR: 3.85, 95%CI: 2.45–6.07, n = 8, I2 = 67.0%), high triglycerides
(OR: 1.46, 95%CI: 1.21–1.75, n = 14, I2 = 10.0%) and high LDL-cholesterol (OR: 2.38, 95%
CI: 1.43–3.95, n = 11, I2 = 87.6%). ART was associated with rather lower odds of having low
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HDL-cholesterol (OR: 0.53, 95%CI: 0.32–0.87, n = 8, I2 = 78.2%). There was evidence of
between-study heterogeneity for all outcomes except high triglycerides.
Conclusions
ART appears to be associated with CVD risk in HIV/AIDS patients in SSA only through dysli-
pidemia but not through hypertension and DM, however, high quality and robust research in
SSA is mandated to accurately ascertain the actual contribution of ART to the CVD burden
in this part of the world. Nevertheless, HIV/AIDS patients should still benefit from systematic
CVD screening alongside their regular care services.
Trial registration
Prospero Registration - CRD42016042306.
Introduction
Sub-Saharan Africa (SSA) remains the region most affected by HIV/AIDS with an estimated
25.5 million cases, 1.4 million new infections and 0.8 million AIDS-related deaths in 2015 [1].
The introduction of antiretroviral therapy (ART) and the continuous scale up of its coverage
to about 46% globally and 47% in SSA in 2015, has significantly helped to reduce AIDS-related
morbidity and mortality over the years, with a 45% global reduction in deaths since 2005 [1].
Cardiovascular disease (CVD), which collectively refers to the diseases involving the heart and
blood vessels, is a major public health problem, accounting for 37% of all non-communicable
disease-related deaths globally in 2012 [2]. Contrary to HIV/AIDS, the CVD epidemic has
been steadily on the rise in Low and Middle-Income countries (LMICs) with over three quar-
ters of global CVD-related deaths occurring in these countries [2]. This CVD epidemic is
largely due to the increasing incidence of its major risk factors; hypertension (HTN); diabetes
mellitus (DM), and abnormal blood lipid levels (high total cholesterol (TC), high serum tri-
glycerides (TG), low high density lipoprotein cholesterol (HDL) and high low density lipopro-
tein cholesterol (LDL)) [3]. Of more concern is the increasingly observed higher CVD
occurrences in the HIV-infected population compared to HIV negative control subjects [4–6],
and the higher CVD rates in ART-treated compared to ART-naïve patients, suggestive of a
probable association between ART and these CVD risk factors [4–13]. However, assessing the
association between ART and CVD risk factors has been markedly confounded by the prevail-
ing epidemiological transition towards rising incidence and prevalence of non-communicable
diseases. A systematic review on this probable association between ART and CVD among
HIV-infected patients in SSA found significantly higher rates of adverse cardio-metabolic
traits in patients on ART compared to ART-naïve individuals, attributing this difference to
ART use [5]. However, this review compared the standardized mean differences in blood pres-
sure, blood glucose and lipid profile parameters between the various patient groups and was
not actually on hypertension, diabetes or dyslipidemia respectively, which are more precise
and relevant measures of adverse disease outcomes. Moreover, more studies especially in SSA
with varying conclusions on this subject have been published after the former review. This
study was therefore conducted to systematically review and summarize published studies on
the extent to which exposure to ART is associated to these CVD risk factors in SSA, given the
specificities of HIV/AIDS and access to ART in the SSA region. We had as specific objectives
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to estimate overall measures of effect for the association between ART and hypertension, dia-
betes mellitus and dyslipidemia (elevated total cholesterol, triglycerides and low density lipo-
protein cholesterol and reduced high density lipoprotein cholesterol) respectively in HIV/
AIDS patients in SSA.
Methods
Search strategy and selection criteria
This was a systematic review and meta-analysis of published studies on the association
between ART use and the selected CVD risk factors (hypertension, diabetes mellitus, and
dyslipidemia).
The search was completed in December 2017 and the following databases were searched:
Medline (1946–2017), Embase (1947–2017) Africa-wide Information (1960–2017), the
Cochrane library (1996–2017) and African Index Medicus (2002–2017). The search was cen-
tered around the 3 key concepts; anti-retroviral therapy; cardiovascular disease risk factors
(hypertension, diabetes, dyslipidemia) and sub-Saharan Africa (each sub-Sahara African coun-
try included). For each key concept, the subject heading search was combined to the free-text
search of the synonyms and derivatives of the main concept using the boolean operator ‘OR’,
then these results from the 3 key words were combined all together using the boolean operator
‘AND’. The search strategy conducted for Ovid Medline and Ovid Embase is presented in S1
Table. Articles returned by the search were saved on the Zotero version 4.0.29.10 reference
manager software for removal of duplicates and screening of titles and abstracts of articles.
The full text of the remaining articles were then reviewed for eligibility in accordance with the
selection criteria by two investigators (CAD and HB).
The following studies were included:
• Cross-sectional, cohort, case-control and randomized controlled trials with data on the prev-
alence or incidence of hypertension, DM or lipid profile disorders in HIV/AIDS patients.
• Studies with comparable ART-treated and ART-naïve populations.
• Studies published in English up to July 2017 in the selected databases.
• Studies involving participants aged 18 and above, living in one of the countries in SSA.
Studies excluded were:
• Unpublished manuscripts and conference abstracts.
• Studies that only compared the mean blood pressure, glucose and lipid levels in the ART-
treated and ART-naïve groups rather than the actual prevalence or incidence of hyperten-
sion, DM and dyslipidemia.
• Studies from which we could not calculate the relevant CVD risk factor parameters or the
measures of effect from the provided data
• Studies with diagnostic criteria and cut-off values for hypertension, DM and abnormal lipid
profiles different from those internationally recognized.
• Same studies published in different journals with the same or a different title.
For cohort studies with several publications of their results over time, the most recent of the
studies was used. The reference lists of relevant articles were also searched for eligible studies.
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Data analysis
Data were abstracted from eligible studies onto the pre-tested data abstraction form produced
on Epi info version 7.1.0.6 statistical software (CDC, Atlanta, USA) by the principal investiga-
tor (CAD) and reviewed by a second investigator (HB). The following data were abstracted:
First author, publication year, journal, study period, study design and setting, socio-demo-
graphic and clinical information of the participants such as mean or median age, sex distribu-
tion, duration of HIV infection and of ART use, ART regimens, the measures of disease
frequency and effect for the cardiovascular risk factors (hypertension, DM and abnormal lipid
profiles) in the ART and ART-naïve groups. When not directly available, the appropriate mea-
sures of effect such as the odds ratios for the outcomes were derived from the reported data
and entered into the abstraction form. The data were doubled-checked for errors and accuracy
after completion of abstraction and exported to STATA version 14.1 statistical software for
analysis.
The exposure variable was ART use, categorized into: ART and ART-naïve groups for
patients who had ever received ART and those who had never received ART respectively. The
outcome variables were the presence of hypertension, diabetes and abnormal lipid profiles/
dyslipidemia (high TC, high TG, low HDL-cholesterol and high LDL-cholesterol) respectively.
These outcomes were defined according to their respective standard International criteria (S2
Table). The odds ratio was used as the measure of effect to compare the outcome in the ART
and ART-naïve groups. Crude odds ratios were derived from the raw data extracted from the
studies and adjusted odds ratios were preferentially used when reported. Pooled estimates of
the odds ratios for the outcomes comparing the ART and ART-naïve groups were derived
using random effects meta-analysis and presented on Forest plots showing both the size and
direction of the overall effect. The Cochran’s Q test was performed for evidence of heterogene-
ity across studies with low P values suggestive of between-study heterogeneity. The I2 test sta-
tistic was also used to assess the degree of heterogeneity among the studies, reported as the
percentage of between-study variability not due to chance [14]. The Harbord’s test and the
Peter’s test [15], were used to statistically assess for funnel plot asymmetry and small-study
effects. Meta-regressions and subgroup stratified analyses were also done according to the
study quality, study location, sample size and adjusting of confounders or not, to explore
potential sources of heterogeneity among the studies.
All studies were assessed for their quality and risk of bias using the Quality Assessment
Tool for Observational Cohort and Cross-Sectional Studies of the National Health Institute
(National Heart, Lung, and Blood Institute) and given an overall rating of good, fair or poor
based on well-defined criteria [16]. Studies were assessed for their research questions and
objectives, their study populations, sample sizes and participation rates, the validity, reliability
and consistency in the measurement of exposure and outcome variables among study partici-
pants, and the measurement and adjustment of potential confounders (S3 Table).
The Grading of Recommendations Assessment, Development and Evaluation (GRADE)
approach was also used to assess the quality of evidence with respect to each specific outcome
[17]. The overall quality of evidence on these various outcomes was graded as high, moderate,
low or very low (S4 Table).
This review was reported in accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) 2009 guidelines (S5 Table). Prospero Registration—
CRD42016042306
The Research Governance and Integrity Office of the Research Ethics Committee of the
London School of Hygiene and Tropical Medicine reviewed the study protocol and assessed
the study as not requiring an ethical approval (LSHTM Ethics Reference: 11026).
Association between antiretroviral therapy and cardiovascular disease risk factors in sub-Saharan Africa
PLOS ONE | https://doi.org/10.1371/journal.pone.0201404 July 30, 2018 4 / 19
Results
Fig 1 presents a flow chart of the study selection process, with the number of articles retrieved
at each stage from the search results through the title and full-text review to the studies finally
included in the review. The search strategy returned a total of 3581 articles, to which 11 studies
were added from the search of the reference list of relevant studies, and 372 duplicates were
removed. From the 3220 records left, 3180 were excluded since they were out of scope and not
in sub-Saharan Africa, leaving 40 potentially eligible studies for full text review. Twenty studies
Fig 1. PRISMA flow chart detailing the study selection process.
https://doi.org/10.1371/journal.pone.0201404.g001
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were subsequently excluded based on the selectin criteria (12 not comparing ART and ART-
naïve groups, 4 with more recent updates of their findings, 3 conference abstracts, 3 comparing
means rather than proportions of the outcome measures, and 1 not on CVD risk factors).
Twenty studies were finally included in the analysis [13,18–36]. These studies included a total
of 5386 participants (Table 1). A general summary of all the included studies and the 20
excluded studies including the reasons for their exclusion are presented on S6 and S7 Tables
respectively. All the studies included were cross-sectional in design and participants were
recruited in hospital settings. There was no difference in the overall mean percentage of males
(30.7±8.1 vs 34.4±9, p = 0.271, n = 14), mean BMI (23.9±1.3 vs 23.1±1.5, p = 0.124, n = 16) and
CD4 cell count (382±59 vs 322±100, p = 0.073, n = 13) between the ART and the ART-naïve
groups respectively. The group on ART was older than the ART-naïve group (mean age: 39.2
±3.5 vs 36.8±3.4 years, p = 0.042, n = 18). The median of the mean or median duration of ART
use in the respective studies was 38 months (interquartile range: 30–56). Overall 9 studies were
rated as being of good quality and 11 as being of fair quality based on the assessment criteria
(S3 Table). The GRADE evidence profile for the assessed outcomes has been presented on S4
Table. Overall, the quality of evidence on high TC, low HDL-cholesterol and high LDL-choles-
terol was moderate given the overall strengths of the associations observed, while that on
hypertension, DM and high TG were rated as low given the combinations of inconsistencies,
publication bias (high TG) and weak overall strengths of association. Graphical evidence of
publication bias for the respective outcomes have been presented on S1–S6 Figs.
Eight studies reported on the association between ART use and hypertension [13,21,23–
25,28,30,32]. Of these studies, only 4 had strong evidence of a significant association, all in
favor of higher odds of HTN in patients on ART [13,24,28,30]. The pooled estimate suggests
the absence of any statistically significant association between ART use and HTN (OR: 1.90,
Table 1. Socio-demographic characteristics of the participants from the eligible studies.
# Author (Year) Country Study Years Parti-cipants Males (%) Age in years ART duration (months)
1 Abebe (2014) Ethiopia 2011–2012 252 27.8 35.3 -
2 Awotedu (2010) South Africa 2009–2010 196 18.9 36.9 -
3 Ayodele (2012) Nigeria - 291 32.6 39.5 17.2
4 Botha (2014) South Africa - 137 - 43.0 34.2
5 Dave (2011) South Africa - 849 - - 16.0
6 Dimala (2016) Cameroon 2013 200 30.0 39.1 58.6
7 Ekali (2013) Cameroon - 143 28.0 39.5 -
8 Maganga (2015) Tanzania - 301 - - 56.0
9 Manuthu (2008) Kenya 2006 295 42.0 - -
10 Mbunkah (2014) Cameroon 2010–2011 173 28.9 38.7 -
11 Mohammed (2015) Ethiopia 2014 393 33.1 - -
12 Muhammad (2013) Nigeria 2009 200 47.0 32.5 -
13 Ngala (2013) Ghana 2009–2010 305 - - -
14 Nsagha (2015) Cameroon 2014 215 25.1 43.2 62.7
15 Ogundahunsi (2008) Nigeria - 110 - - -
16 Ogunmola (2014) Nigeria - 250 37.6 37.6 34.1
17 Osegbe (2016) Nigeria - 200 - 36.6 -
18 Pefura Yone (2011) Cameroon 2009–2010 276 39.1 39.6 30.2
19 Tadewos (2012) Ethiopia 2012 226 35.0 35.5 49.4
20 Tesfaye (2014) Ethiopia 2012–2013 374 33.7 - 42.6
 Mean/median
https://doi.org/10.1371/journal.pone.0201404.t001
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95% CI: 0.96–3.76, p = 0.065) (Table 2 & Fig 2). The studies were heterogeneous (p<0.001)
with a 73.8% variation across studies (I2). There was weak evidence of publication bias statisti-
cally (Harbord’s test p = 0.926 and Peter’s test p = 0.403).
Table 2. Individual and pooled odds ratios of the studies reporting the association between ART use and hypertension.
Author (Year) Proportion of ART+ with HTN (%) Proportion of ART-naïve with HTN (%) Crude /Adjusted Odds Ratio (95% CI) P value
Manuthu (2008) 18/134 (13.4) 24/161 (14.9) 0.89 (0.46–1.71) 0.425
Muhammad (2013) 17/100 (17.0) 2/100 (2.0) 10.03 (2.25–44.71) <0.001
Ekali (2013) 18/115 (15.7) 3/28 (10.7) 1.55 (0.42–5.67) -
Ogunmola (2014) 16/130 (12.3) 19/120 (15.8) 0.68 (0.17–2.72) 0.587
Botha (2014) 20/66 (30.3) 29/71 (40.8) 0.63 (0.31–1.28) 0.280
Nsagha (2015) 47/160 (29.4) 8/55 (14.5) 2.44 (1.07–5.57) 0.033
Maganga (2015) 43/150 (28.7) 8/151 (5.3) 7.183 (3.24–15.91) -
Dimala (2016) 38/100 (38.0) 19/100 (19.0) 2.20 (1.07–4.52) 0.032
Pooled Estimate Heterogeneity P<0.001, I2 = 78.3% 1.90 (0.96–3.76) 0.065
Heterogeneity P<0.001, I2 = 78.3%
 Adjusted odd ratios obtained from the logistic regression models of the respective studies.
https://doi.org/10.1371/journal.pone.0201404.t002
Fig 2. Forest plot of the studies reporting the association between ART use and hypertension. The solid line on the Forest plot is the point of no effect (OR = 1) and
the dashed line represents the overall pooled estimate. The grey squares and horizontal lines represent the odds ratios of each study and their 95% confidence intervals.
The size of the grey square represents the weight contributed by each study in the meta-analysis. The diamond represents the pooled odds ratio and its 95% confidence
intervals.
https://doi.org/10.1371/journal.pone.0201404.g002
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Eight studies reported on DM [22–24,27–30,33], and 3 of these studies found statistically
higher odds of DM in patients on ART (Table 3 & Fig 3) [27,29,33]. Overall, there was no sta-
tistically significant association between DM and ART use (Pooled estimate: 2.53, 95% CI:
0.87–7.35, p = 0.089), and a significant between-study heterogeneity (p<0.001, I2 statis-
tic = 70.7%). There was no statistical evidence of publication bias (Harbord’s test p = 0.347 and
Peter’s test p = 0.788).
All 8 studies that reported on total cholesterol found higher odds of having a high TC level
in patients receiving ART compared to ART-naïve patients [18,23,25,28,30,33–35]. The overall
pooled estimate was 3.85 (95% CI: 2.45–6.07, p<0.001), the between study heterogeneity
p = 0.003 and I2 statistic = 67.0%. (Table 4 & Fig 4) and the Harbord’s test and the Peter’s test
p values for small study effect were 0.740 and 0.871 respectively.
Fourteen studies reported on the association between ART use and high TG [18–
20,23,25,26,28–31,33–36]. The pooled estimate was in favor of an association between ART
use and high TG (OR: 1.46, 95% CI: 1.21–1.75, p<0.001) (Table 5 & Fig 5). There was no evi-
dence of heterogeneity among the studies (p = 0.344, I2 statistic = 10.0%).There was some evi-
dence of publication bias (Harbord’s and Peter’s test p values of 0.909 and 0.052 respectively).
Of the 11 studies that reported on low HDL-cholesterol [18–20,25,26,28,30,33–36], all but
two of them found higher odds of low HDL-cholesterol in ART-naïve patients compared to
patients on ART [18,34], The pooled estimate was 0.53 (95% CI: 0.3 2–0.87, p = 0.014) and
there was between-study heterogeneity (p<0.001, I2 statistic = 87.4%) (Table 6 & Fig 6) but no
statistical evidence of publication bias (Harbord’s test P = 0.765 and Peter’s test = 0.936).
The pooled estimate from the 8 studies with reports on high LDL-cholesterol
[18,19,25,28,30,33–35], was suggestive of an association between high LDL-cholesterol and
ART use (OR:2.38, 95%CI: 1.43–3.95, p = 0.001) (Table 7 & Fig 7). There was strong evidence
of study heterogeneity (p = 0.001), with a 78.2% (I2) total variation across studies. The Har-
bord’s and Peter’s test P values were 0.909 and 0.052 respectively.
Study quality was categorized as good and fair, study location categorized into West or Cen-
tral Africa and East or Southern Africa, sample size grouped as 250 and< 250 participants,
and lastly studies were categorized as having adjusted for confounders or not. The between-
stratum and within-stratum heterogeneity P values and I2 statistics were derived. Comparing
the ART to the ART-naïve group, the pooled estimate was higher among studies of good qual-
ity compared to those of fair quality for all measured outcomes except for DM (meta-regres-
sion relative OR:0.38), suggesting a stronger association between ART use and the outcomes
in studies of good quality. On the other hand the pooled estimate was lower in studies that
adjusted for confounders compared to those that did not for, except for high TG and high
Table 3. Pooled and individual odds ratios of the studies reporting the association between ART use and diabetes mellitus.
Author (year) Proportion of ART+ with DM (%) Proportion of ART- with DM (%) Crude/Adjusted Odds Ratio (95% CI) P value
Dave (2011) 10/443 (2.3) 14/406 (3.4) 0.66 (0.28–1.47) 0.292
Ngala (2013) 17/164 (10.4) 3/141 (2.1) 5.32 (1.53–18.56) 0.007
Muhammad (2013) 3/100 (3.0) 3/100 (3.0) 1.00 (0.20–5.08) 1.000
Ekali (2013) 4/115 (3.4) 1/28 (3.6) 0.973 (0.10–9.06) 0.610
Nsagha (2015) 3/160 (1.9) 2/55 (3.6) 0.51 (0.08–3.11) 0.463
Mohammed (2015) 24/284 (8.5) 1/109 (0.9) 9.97 (1.33–74.62) 0.006
Maganga (2015) 27/150 (18.0) 1/151 (0.7) 32.93 (4.41–245.77) -
Osegbe (2016) 9/100 (9.0) 2/100 (2.0) 4.86 (1.02–23.03) 0.030
Pooled Estimate 2.53 (0.87–7.35) 0.089
Heterogeneity P<0.001, I2 = 70.7%
https://doi.org/10.1371/journal.pone.0201404.t003
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Fig 3. Forest plot of the studies reporting the association between ART use and diabetes mellitus. The solid line on the Forest plot is the point of no effect (OR = 1)
and the dashed line represents the overall pooled estimate. The grey squares and horizontal lines represent the odds ratios of each study and their 95% confidence
intervals. The size of the grey square represents the weight contributed by each study in the meta-analysis. The diamond represents the pooled odds ratio and its 95%
confidence intervals.
https://doi.org/10.1371/journal.pone.0201404.g003
Table 4. Pooled and individual odds ratios of the studies reporting the association between ART use and high total cholesterol.
Author (year) Proportion of ART+ with high TC (%) Proportion of ART- with high TC (%) Crude/Adjusted Odd ratios (95% CI) P value
Manuthu (2008) 51/134 (38.1) 16/161 (9.9) 5.81 (3.10–10.9) <0.001
Pefura Yone (2011) 52/138 (37.7) 33/138 (23.9) 1.82 (1.06–3.12) 0.020
Tadewos (2012) 49/113 (43.4) 18/113 (15.9) 3.8 (1.34–7.44) <0.001
Muhammad (2013) 31/100 (31.0) 7/100 (7.0) 5.97 (2.48–14.35) <0.001
Ekali (2013) 33/115 (28.7) 3/28 (10.7) 3.35 (0.95–11.87) -
Abebe (2014) 53/126 (42.0) 14/126 (11.1) 5.82 (3.00–11.22) <0.001
Nsagha (2015) 80/160 (50.0) 6/55 (10.9) 8.17 (3.31–20.14) <0.001
Osegbe (2016) 47/100 (47.0) 34/100 (34.0) 1.72 (0.97–3.05) 0.060
Pooled Estimate 3.85 (2.45–6.07) <0.001
Heterogeneity P = 0.003, I2 = 67.0%
 Adjusted odd ratios obtained from the logistic regression models of the respective studies.
https://doi.org/10.1371/journal.pone.0201404.t004
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LDL-cholesterol (meta-regression relative OR:1.84 and 1.12 respectively). Overall, there was
no statistical evidence that the between-study heterogeneity could be explained by any of these
study characteristics (S8 Table).
Discussion
This study aimed to assess the extent to which exposure to ART is associated with selected
CVD risk factors in SSA by reviewing published studies with measures of effect on this associa-
tion and deriving corresponding pooled estimates of these measures through meta-analysis.
Contrary to the previous studies that reported on an association between ART and hyperten-
sion and/or diabetes, this review found no significant direct association between hypertension,
diabetes and ART, and suggests this observation could rather be due to the dyslipidemia asso-
ciated with ART use.
Though patients on ART were found to have a 90% higher odd of having hypertension
compared to their ART naïve counterparts, the association between ART and hypertension
from the aggregated 8 studies was not statistically significant. It is worth noting that one of the
four studies that found no association between ART and hypertension, however, reported that
Fig 4. Forest plot of the studies reporting the association between ART use and high total cholesterol. The solid line on the Forest plot is the point of no effect
(OR = 1) and the dashed line represents the overall pooled estimate. The grey squares and horizontal lines represent the odds ratios of each study and their 95%
confidence intervals. The size of the grey square represents the weight contributed by each study in the meta-analysis. The diamond represents the pooled odds ratio and
its 95% confidence intervals.
https://doi.org/10.1371/journal.pone.0201404.g004
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the prevalence of hypertension significantly increased as treatment duration increased [23]. As
such, the inclusion of patients on ART for very short durations in that study and the inclusion
of such studies with low median ART durations in our analyses could have contributed to
diminishing the observed effect of ART on blood pressure. This was earlier mentioned by stud-
ies which suggested that the effects of ART on blood pressure are best appreciated after pro-
longed exposure to ART [37,38]. There was no evidence of publication bias and the meta-
regression analysis exploring the observed heterogeneity between the studies did not find any
particular study characteristic that could explain this inconsistency in studies. However, the
sub-group analysis was limited to study quality, study location, sample size and adjustment for
confounders and did not include important parameters such as age and duration of ART use
since they were not provided by all the studies. The review by Dillon et al conducted in SSA
had findings similar to those of this review with no association between ART use and higher
blood pressure values [5]. This finding is, however, contrary to that of a more recent review by
Nduka et al which found a significantly higher risk of hypertension associated with ART use
worldwide [12]. Just a quarter of the studies in the latter review were from SSA with contrast-
ing findings on this association. The effect of ART on blood pressure should be considered
and addressed together with other factors such as environmental factors, genetic and lifestyle
predispositions to hypertension.
There was also no significant association between ART use and DM. This finding is similar
to that earlier reported by Dillon et al who did not observe any association between ART use
and fasting blood glucose levels in SSA [5]. Some large prospective studies have reported an
association between ART and DM [10,39,40]. and the studies by Brown et al[10] and Tien et al
[39] had HIV-uninfected patients as control subjects making it challenging to attribute the
observed association solely to ART use given the fact that HIV infection itself has been associ-
ated to some extent to DM [41]. Also the large cohort study by De Wit et al [40] consisted of
participants from Europe, South and North America and Australia but not SSA raising up the
question if the effect of ART on glucose metabolism varies with ethnicity. Even though the
Table 5. Pooled and individual odds ratios of the studies reporting the association between ART use and high serum triglyceride.
Author (year) Proportion of ART+ with high TG (%) Proportion of ART- with high TG (%) Crude/Adjusted Odd ratios (95% CI) P value
Ogundahunsi (2008) 8/55 (14.5) 1/55 (1.8) 9.19 (1.11–76.23) -
Manuthu (2008) 33/134 (24.6) 36/161 (22.3) 1.18 (0.69–2.04) -
Awotedu (2010) 24/86 (27.9) 15/110 (13.6) 2.45 (1.19–5.03) -
Pefura Yone (2011) 60/138 (43.5) 53/138 (38.4) 1.23 (0.76–2.00) 0.392
Tadewos (2012) 63/113 (55.8) 35/113 (31.0) 2.5 (1.41–4.42) 0.002
Ayodele (2012) 8/236 (3.4) 8/55 (14.5) 0.86 (0.37–1.99) 0.716
Ngala (2013) 34/164 (20.7) 28/141 (19.9) 1.1 (0.60–1.85) 0.829
Muhammad (2013) 19/100 (19.0) 13/100 (13.0) 1.57 (0.73–3.38) 0.247
Ekali (2013) 3/115 (2.6) 1/28 (3.6) 0.43 (0.07–0.72) 0.630
Mbunkah (2014) 16/112 (14.3) 7/61 (11.5) 1.29 (0.50–3.32) -
Tesfaye (2014) 85/188 (45.2) 69/186 (37.1) 1.40 (0.93–2.11) -
Abebe (2014) 59/126 (46.8) 39/126 (31.0) 1.96 (1.19–3.29) 0.010
Nsagha (2015) 33/160 (20.6) 9/55 (16.4) 1.33 (0.59–2.99) 0.493
Osegbe (2016) 24/100 (24.0) 21/100 (21.0) 1.19 (0.61–2.31) 0.610
Pooled Estimate 1.46 (1.21–1.75) <0.001
Heterogeneity P = 0.344, I2 = 10.0%
 Adjusted odd ratios obtained from the logistic regression models of the respective studies.
https://doi.org/10.1371/journal.pone.0201404.t005
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studies with evidence of no association between ART use and DM were of higher quality than
those that found an association, the meta-regression analysis did not identify the studies’ qual-
ity as a possible explanation for the heterogeneity in the studies.
There was a strong association between ART use and abnormal lipid parameters implying
that patients on treatment are at a greater risk of having these CVD risk factors. These findings
are largely consistent with those of a recent review associating ART to dyslipidemia [42]. Dil-
lon et al in the review in SSA found no association between ART and high TG, and explained
this was probably due to the relatively greater use of NNRTI-based regimes compared to PI-
based regimens, known to induce more dyslipidemia [42]. The studies reporting on these lipid
disorders with the exception of high TG, were heterogeneous and the meta-regression did not
identify any study characteristic that could explain this observation. This actual heterogeneity
among studies could therefore be a possible explanation for the funnel plots asymmetry, since
statistical evidence for small-study effects and publication bias in these cases were
inconclusive.
Fig 5. Forest plot of the studies reporting the association between ART use and high serum triglyceride. The solid line on the Forest plot is the point of no effect
(OR = 1) and the dashed line represents the overall pooled estimate. The grey squares and horizontal lines represent the odds ratios of each study and their 95%
confidence intervals. The size of the grey square represents the weight contributed by each study in the meta-analysis. The diamond represents the pooled odds ratio and
its 95% confidence intervals.
https://doi.org/10.1371/journal.pone.0201404.g005
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Most studies did not report the exact proportions of patients on specific ART regimens to
enable us to assess associations between individual ART agents and the respective CVD risk
factors but many more studies reported the use of NNRTIs over PIs as is currently the case
with first-line regimens in SSA. Associations of greater magnitude could therefore be observed
in settings with predominantly PI-based regimens which have been identified as inducing
more extreme dyslipidemic profiles compared to NNRTIs [42–44].
Several mechanisms have been proposed as possible pathways through which ART could
lead to this multitude of metabolic abnormalities including chronic inflammation due to the
HIV infection itself, increased circulating inflammatory markers and cytokines involved in
insulin and lipid regulation [45,46], but several unanswered questions still remain with regards
to the exact contribution of ART to CVD. The association of ART to particular CVD risk fac-
tors instead of others invariably suggests that the overall effect of ART in HIV/AIDS patients
depends on the complex interplay and combination of several factors such as genetic and envi-
ronmental predispositions.
It is worth noting that all the studies of this review are limited by their cross-sectional
design. It is not possible to detect if all patients developed hypertension, DM or abnormal lipid
profiles before or after initiating ART making it challenging to ascertain any causality between
ART use and these outcomes. This therefore makes the quality of evidence on these outcomes
low to moderate at best, and ensuing recommendations of low strength. However, the study
aimed to identify any possible association irrespective of its nature, and reverse causality in
this case is less likely since the presence of hypertension, DM or dyslipidemia is unlikely to
result in ART use. Selectively exposing patients to ART and monitoring for outcomes that
could take years to occur is even more challenging and involves enormous ethical and logistic
considerations. Such intervention studies are therefore difficult to come by, leaving cross-sec-
tional studies as the primary sources of evidence to answer these research questions.
Some studies had small sizes with no statistical justifications for these, implying they had
greater sampling errors and lower statistical power to detect actual associations that might
have occurred not merely due to chance. This makes their findings less reliable. In addition to
this, not all studies reported the durations of ART among their participants, and there were
differences in ART duration among studies that reported these, increasing the between-study
Table 6. Pooled and individual odds ratios of the studies reporting the association between ART use and low HDL-cholesterol.
Author (year) Proportion of ART+ with low HDLc (%) Proportion of ART- with low HDLc (%) Crude/Adjusted Odd ratios (95% CI) P value
Manuthu (2008) 19/134 (0.14) 82/161 (50.9) 0.16 (0.09–0.29) <0.001
Awotedu (2010) 44/86 (51.2) 72/110 (65.5) 0.55 (0.31–0.99) -
Pefura Yone (2011) 55/138 (39.9) 51/138 (37.0) 1.13 (0.70–1.84) 0.620
Tadewos (2012) 49/113 (0.43) 72/113 (63.7) 0.44 (0.25–0.78) 0.005
Ayodele (2012) 126/236 (0.53) 33/55 (60.0) 0.76 (0.42–1.39) 0.786
Muhammad (2013) 61/100 (61.0) 76/100 (76.0) 0.49 (0.27–0.91) 0.022
Mbunkah (2014) 50/112 (44.6) 39/61 (63.9) 0.46 (0.24–0.86) -
Tesfaye (2014) 101/188 (53.7) 147/186 (79.0) 0.31 (0.20–0.49) -
Abebe (2014) 62/126 (49.2) 34/126 (27.0) 2.62 (1.55–4.44) 0.001
Nsagha (2015) 23/160 (14.4) 8/55 (14.5) 0.99 (0.41–2.35) 0.975
Osegbe (2016) 11/100 (11.0) 42/100 (42.0) 0.17 (0.08–0.36) 0.001
Pooled Estimate 0.53 (0.32–0.87) 0.014
Heterogeneity P<0.001, I2 = 87.4%
 Adjusted odd ratios obtained from the logistic regression models of the respective studies.
https://doi.org/10.1371/journal.pone.0201404.t006
Association between antiretroviral therapy and cardiovascular disease risk factors in sub-Saharan Africa
PLOS ONE | https://doi.org/10.1371/journal.pone.0201404 July 30, 2018 13 / 19
Fig 6. Forest plot of the studies reporting the association between ART use and low HDL-cholesterol. The solid line on the Forest plot is the point of no effect
(OR = 1) and the dashed line represents the overall pooled estimate. The grey squares and horizontal lines represent the odds ratios of each study and their 95%
confidence intervals. The size of the grey square represents the weight contributed by each study in the meta-analysis. The diamond represents the pooled odds ratio and
its 95% confidence intervals.
https://doi.org/10.1371/journal.pone.0201404.g006
Table 7. Pooled and individual odds ratios of the studies reporting the association between ART use and high LDL-cholesterol.
Author (year) Proportion of ART+ with high LDLc (%) Proportion of ART- with high LDLc (%) Crude/Adjusted Odd ratios (95% CI) P value
Manuthu (2008) 53/134 (39.6) 18/161 (11.1) 5.43 (2.97–9.92) <0.001
Awotedu (2010) 67/86 (77.9) 95/110 (86.4) 0.56 (0.26–1.17) -
Pefura Yone (2011) 64/138 (46.4) 29/138 (21.0) 2.99 (1.74–5.15) <0.001
Tadewos (2012) 38/113 (33.6) 17/113 (15.0) 2.64 (1.31–5.32) 0.006
Muhammad (2013) 36/100 (36.0) 26/100 (26.0) 1.60 (0.87–2.93) 0.126
Abebe (2014) 29/126 (23.0) 9/126 (7.1) 3.89 (1.76–8.61) <0.001
Nsagha (2015) 58/160 (36.3) 5/55 (9.1) 5.69 (2.15–15.06) <0.001
Osegbe (2016) 37/100 (37.0) 30/100 (30.0) 1.37 (0.76–2.47) 0.290
Pooled Estimate 2.38 (1.43–3.95) 0.001
Heterogeneity P<0.001, I2 = 78.2%
 Adjusted odd ratios obtained from the logistic regression models of the respective studies.
https://doi.org/10.1371/journal.pone.0201404.t007
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heterogeneity. Also few studies adjusted for the major confounders either at the methodologi-
cal or the statistical phases, making residual confounding a possible explanation for the
observed associations. Despite these limitations, this study remains important as one of the
few systematic reviews and meta-analysis providing epidemiological, clinical and public health
data on HIV/AIDS and CVD in SSA. An extensive search strategy was used and several data-
bases searched making the review exhaustive on the subject.
In conclusion, contrary to the previous reports of an association between hypertension, dia-
betes and ART, this review suggests there is no direct association between hypertension and
diabetes. The associations often observed between ART and these CVD risk factors could be as
a result of its association to dyslipidemia (hypercholesterolemia, hypertriglyceridemia, high
LDL-cholesterol blood levels) as found in this review. This review, however, exposes the
utmost need of high quality and robust research on this subject in SSA to ascertain the actual
impact of ART on CVD risk factors and the contribution of specific ART agents to adverse
CVD outcomes. Nevertheless, HIV/AIDS patients should still benefit from systematic CVD
screening for CVD risk factors alongside their regular counselling and care services.
Fig 7. Forest plot of the studies reporting the association between ART use and high LDL-cholesterol. The solid line on the Forest plot is the point of no effect
(OR = 1) and the dashed line represents the overall pooled estimate. The grey squares and horizontal lines represent the odds ratios of each study and their 95%
confidence intervals. The size of the grey square represents the weight contributed by each study in the meta-analysis. The diamond represents the pooled odds ratio and
its 95% confidence intervals.
https://doi.org/10.1371/journal.pone.0201404.g007
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S1 Fig. Funnel Plot for studies on the association between HAART use and hypertension
with log odds ratios displayed on the horizontal scale. The blue dots represent the studies,
the solid vertical line represents the log odds ratio of the pooled estimate obtained from the
meta-analysis, the dashed diagonal lines represent the 95% confidence limits around the
pooled estimate.
(TIF)
S2 Fig. Funnel plot for studies on the association between HAART use and diabetes melli-
tus with log odds ratios displayed on the horizontal scale. The blue dots represent the stud-
ies, the solid vertical line represents the log odds ratio of the pooled estimate obtained from the
meta-analysis, the dashed diagonal lines represent the 95% confidence limits around the
pooled estimate.
(TIF)
S3 Fig. Funnel plot for studies on the association between HAART use and high total cho-
lesterol with log odds ratios on the horizontal scale. The blue dots represent the studies, the
solid vertical line represents the log odds ratio of the pooled estimate obtained from the meta-
analysis, the dashed diagonal lines represent the 95% confidence limits around the pooled esti-
mate.
(TIF)
S4 Fig. Funnel plot for studies on the association between HAART use and high triglycer-
ides respectively with log odds ratios on the horizontal scale. The blue dots represent the
studies, the solid vertical line represents the log odds ratio of the pooled estimate obtained
from the meta-analysis, the dashed diagonal lines represent the 95% confidence limits around
the pooled estimate.
(TIF)
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S5 Fig. Funnel plot for studies on the association between HAART use and low HDL-cho-
lesterol with log odds ratios displayed on the horizontal scale. The blue dots represent the
studies, the solid vertical line represents the log odds ratio of the pooled estimate obtained
from the meta-analysis, the dashed diagonal lines represent the 95% confidence limits around
the pooled estimate.
(TIF)
S6 Fig. Funnel plot for studies on the association between HAART use and high LDL-cho-
lesterol respectively with log odds ratios displayed on the horizontal scale. The blue dots
represent the studies, the solid vertical line represents the log odds ratio of the pooled estimate
obtained using the fixed effects meta-analysis, the dashed diagonal lines represent the 95%
confidence limit around the pooled estimate.
(TIF)
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